Abstract
Background The prognostic value of CD133 and SOX2 expression in advanced cancer remains unclear. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients. Methods Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Trial sequential analysis (TSA) was also performed. Results 13 studies with 1358 cases (CD133) and five studies with 433 cases (SOX2) were identified. CD133 positivity was correlated with worse CSS and OS, but there was no correlation between CD133 positivity and DFS. SOX2 positivity was associated with poor DFS and RFS but was not linked to PFS. Stratified analysis by study source showed that only CD133 positivity can decrease OS for Chinese patients. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. TSA showed that additional studies were necessary. Conclusions CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed. Impact CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients.
Highlights
Cancer is still one of the most threatening diseases worldwide [1]
cancer stem cells (CSCs) are considered to be involved in chemotherapy/radiotherapy resistance, metastasis, and postoperative recurrence [53, 54]
Some meta-analyses showed that CD133 was a biomarker of putative CSCs in many solid tumors and its positivity may be associated with poor overall survival in nonsmallcell lung cancer [55], worse prognosis in patients with glioblastoma [20], and reduced overall survival in colorectal cancer [56]
Summary
Cancer is still one of the most threatening diseases worldwide [1]. surgery, chemotherapy, and/or radiotherapy have greatly improved the clinical survival for early cancer patients, therapies for patients with advanced or metastatic cancer still have a major challenge [2]. Improvements in the treatment of advanced or metastatic cancer patients (surgical technique, chemotherapy, radiotherapy, targeted molecular therapy, and immunotherapy regimens) have extended patients’ median survival, but such as 5-year overall survival is still poor [3,4,5]. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
